How GLP-1 Agonists Improve Metabolic Health in Psoriatic Disease
Why this matters
If you have psoriasis or care for someone who does, you’ve probably noticed it’s more than just a skin issue. At a recent Fall Clinical 2026 panel, dermatologist Joel Gelfand, MD, MSCE, talked about a growing conversation in dermatology: how medicines called GLP-1 agonists might affect psoriasis and a person’s overall health.
Quick summary
Doctors are increasingly thinking beyond clearing visible plaques. Even when skin looks better, many people with psoriasis still have underlying inflammation and metabolic problems such as high blood pressure, insulin resistance, or excess weight. Early research and clinical experience suggest that adding treatments that improve metabolic health — including GLP-1–type medications — may help people feel better overall and could modestly improve skin and joint symptoms. Any treatment decision should be discussed with your doctor.
Psoriasis is more than skin-deep
Psoriasis is an inflammatory condition that most people notice because of red, scaly patches on the skin. But inflammation in psoriasis can affect the whole body. Many people with psoriasis also have higher rates of obesity, high blood pressure, diabetes or prediabetes, and an increased chance of developing psoriatic arthritis.
Dr. Gelfand described psoriasis as an inflammatory metabolic disease, meaning inflammation and metabolic issues like excess weight often go hand in hand. Obesity not only makes psoriasis more likely, it tends to make symptoms worse and can raise the risk of developing joint problems.
Importantly, some people still have signs of systemic inflammation even after their skin clears with treatment. That lingering inflammation may affect long-term health and the durability of skin therapies.
What are GLP-1 agonists and why are dermatologists talking about them?
GLP-1 agonists are a class of medications commonly used to treat type 2 diabetes and to help with weight loss. Because weight and metabolic health are closely linked to psoriasis, some dermatologists are discussing these medicines with patients to consider whether they could be part of a broader treatment plan.
This conversation is not about replacing dermatology treatments but about optimizing overall health. The goal is longer-term remission of skin disease while also addressing blood pressure, blood sugar, and weight.
What the research shows so far
Dr. Gelfand discussed results from the TOGETHER-PsO trial, which looked at combining ixekizumab (a biologic that targets inflammation in psoriasis) with tirzepatide (a medication that affects metabolic pathways). The study reported real improvements in skin and joint symptoms, though those differences were not large.
Where the trial showed more striking change was in metabolic measures. Blood pressure fell by about 8 to 10 mm Hg on average in the group receiving the combination, which is a meaningful difference for cardiovascular risk. The trial’s findings suggest that treating metabolic health alongside skin disease can have important benefits beyond appearance.
These findings were presented at a conference panel and reflect early clinical data. They do not mean every person with psoriasis should start these medicines. More research and personalized medical advice are needed.
What doctors are seeing in clinic
Dermatologists who have discussed or prescribed GLP-1–type medicines report that patients often come back with two pleasant surprises: clearer skin and better health numbers. In roundtable discussions, clinicians described this experience as gratifying. Patients say things like, “My skin is better, and my numbers look better,” which supports the idea that a holistic approach can help multiple aspects of health.
Still, treatment effects vary. Some people see clearer skin and improved joint symptoms; others see mainly metabolic benefits. Decisions about medications should be made with your dermatologist and primary care doctor or endocrinologist.
Keeping an eye on visible changes
If you’re tracking your psoriasis, consider taking photos or notes about how plaques, redness, or joint symptoms change over time. This can help you and your doctor see whether new treatments are making a difference and whether you need further evaluation.
When to talk with your doctor
Discuss a broader treatment plan with your dermatologist if:
- You have persistent psoriasis despite treatment.
- You have concerns about weight, blood pressure, blood sugar, or joint pain.
- Your skin clears but you still feel unwell or have other health risks.
Seek prompt medical advice if you notice rapidly changing lesions, new joint pain, bleeding, signs of skin infection, or any sudden worsening of symptoms.
Short disclaimer
This article summarizes a panel discussion and a clinical trial presented at a conference. It is for informational purposes and is not medical advice. Treatment choices depend on individual medical history and should be made together with your health care team.
Sources
- Panel discussion with Joel Gelfand, MD, MSCE, at Fall Clinical 2026.
- TOGETHER-PsO trial of ixekizumab plus tirzepatide (trial results discussed at Fall Clinical 2026).